Folate Receptor-Mediated Drug Targeting Research Paper
MINIREVIEW
Folate Receptor-Mediated Drug Targeting:
From Therapeutics to Diagnostics
ANDREW R. HILGENBRINK, PHILIP S. LOW
Department of Chemistry, Purdue University, West Lafayette, Indiana 47907
Received 25 May 2005; accepted 27 June 2005
Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.20457
ABSTRACT: Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have …show more content…
CONCLUSIONS
FOLATE-TARGETED IMAGING AGENTS
Due to the over-expression of FR on cancer cells and activated macrophages, folate-targeted imaging agents can serve as noninvasive diagnostic
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 94, NO. 10, OCTOBER 2005
As targeted drug delivery systems move to the forefront of new drug development, targeting ligands like folic acid will undoubtedly be subjected to increasingly greater scrutiny. Where
FOLATE RECEPTOR-MEDIATED DRUG TARGETING
specificity for pathologic cells is high, such targeting ligands can not only facilitate elevated drug uptake by diseased cells, but also greatly reduce collateral toxicity to normal tissues. Due to its ability to target not only FRþ cancers, but …show more content…
52. Roy EJ, Gawlick U, Orr BA, Kranz DM. 2004.
Folate-mediated targeting of T cells to tumors.
Adv Drug Deliv Rev 56:1219–1231.
53. Lu Y, Sega E, Leamon CP, Low PS. 2004. Folate receptor-targeted immunotherapy of cancer:
Mechanism and therapeutic potential. Adv Drug
Deliv Rev 56:1161–1176.
54. Lu Y, Low PS. 2002. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol
Immunother 51:153–162.
55. Lu Y, Low PS. 2003. Immunotherapy of folate receptor-expressing tumors: Review of recent advances and future prospects. J Control Release
91:17–29.
56. Paulos CM, Turk MJ, Breur GJ, Low PS. 2004.
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56:
1205–1217.
57. Gawlick U, Kranz DM, Schepkin VD, Roy EJ.
2004. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjug Chem 15:1137–1145.
58. Kranz DM, Patrick TA, Brigle KE, Spinella MJ,
Roy EJ. 1995. Conjugates of folate and anti-T-cellreceptor antibodies specifically target folatereceptor-positive tumor cells for lysis. Proc Natl
Acad Sci USA
Folate Receptor-Mediated Drug Targeting:
From Therapeutics to Diagnostics
ANDREW R. HILGENBRINK, PHILIP S. LOW
Department of Chemistry, Purdue University, West Lafayette, Indiana 47907
Received 25 May 2005; accepted 27 June 2005
Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.20457
ABSTRACT: Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes that have …show more content…
CONCLUSIONS
FOLATE-TARGETED IMAGING AGENTS
Due to the over-expression of FR on cancer cells and activated macrophages, folate-targeted imaging agents can serve as noninvasive diagnostic
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 94, NO. 10, OCTOBER 2005
As targeted drug delivery systems move to the forefront of new drug development, targeting ligands like folic acid will undoubtedly be subjected to increasingly greater scrutiny. Where
FOLATE RECEPTOR-MEDIATED DRUG TARGETING
specificity for pathologic cells is high, such targeting ligands can not only facilitate elevated drug uptake by diseased cells, but also greatly reduce collateral toxicity to normal tissues. Due to its ability to target not only FRþ cancers, but …show more content…
52. Roy EJ, Gawlick U, Orr BA, Kranz DM. 2004.
Folate-mediated targeting of T cells to tumors.
Adv Drug Deliv Rev 56:1219–1231.
53. Lu Y, Sega E, Leamon CP, Low PS. 2004. Folate receptor-targeted immunotherapy of cancer:
Mechanism and therapeutic potential. Adv Drug
Deliv Rev 56:1161–1176.
54. Lu Y, Low PS. 2002. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol
Immunother 51:153–162.
55. Lu Y, Low PS. 2003. Immunotherapy of folate receptor-expressing tumors: Review of recent advances and future prospects. J Control Release
91:17–29.
56. Paulos CM, Turk MJ, Breur GJ, Low PS. 2004.
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56:
1205–1217.
57. Gawlick U, Kranz DM, Schepkin VD, Roy EJ.
2004. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjug Chem 15:1137–1145.
58. Kranz DM, Patrick TA, Brigle KE, Spinella MJ,
Roy EJ. 1995. Conjugates of folate and anti-T-cellreceptor antibodies specifically target folatereceptor-positive tumor cells for lysis. Proc Natl
Acad Sci USA